Jupiter Expands Nugevia™ Strategy for GLP-1 Users
Jupiter, Florida | January 28, 2026 — Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, announced a strategic expansion of...
Clinical-Stage Biotech
Advertisement
TRexBio Secures $50M to Advance Precision Treg Therapies
SOUTH SAN FRANCISCO, CALIFORNIA | January 27, 2026 — TRexBio, Inc., a clinical-stage biotechnology company focused on precision immunoregulatory...
Phio Pharmaceuticals Highlights siRNA Oncology Program at DealFlow
KING OF PRUSSIA, PENNSYLVANIA | January 26, 2026 — Phio Pharmaceuticals has announced its participation in the Third Annual...
FibroBiologics to Present at Global Healthcare Investment Forum
HOUSTON | January 6, 2026 — FibroBiologics, Inc. announced that its Founder and Chief Executive Officer will present at...
GenEditBio Wins FDA IND Clearance for GEB-101 Therapy
HONG KONG | January 5, 2026 — GenEditBio has received U.S. FDA clearance of its Investigational New Drug (IND)...
Advertisements
Phio Advances PH-762 With FDA-Backed Toxicology Study
King of Prussia, Pennsylvania | December 23, 2025 — Phio Pharmaceuticals Corp. announced a significant advancement in its drug...
NervGen Aligns Capital Strategy to Advance Regenerative Clinical R&D
VANCOUVER, Canada — December 12, 2025 — NervGen Pharma Corp., a clinical-stage biopharmaceutical company developing regenerative therapies for neurological...
NKGen Biotech Issues Statement on New Board Appointments at NKGen Korea
Santa Ana, California, December 3, 2025 — NKGen Biotech has issued an official statement regarding new board appointments at...
Tectonic Therapeutic Highlights GPCR Program at Investor Events
Watertown, Mass. — December 1, 2025 — Tectonic Therapeutic, Inc. announced that its executive leadership will participate in two...
NRG Therapeutics Expands Leadership to Accelerate Drug Pipeline
Stevenage, United Kingdom, December 1, 2025 NRG Therapeutics has announced the appointment of Dr. Paul Thompson as Chief Development...
Advertisement
